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Clotting linked to a memory maker
A chemical that boosts our ability to learn and remember also boosts blood 
clotting, say Morrell et al. (page 575).
The learning chemical, glutamate, is released at neuronal synapses, 
where it activates neurons by binding to ion channel receptors. 
Glutamate is also abundant in the blood—particularly in clot-forming 
platelets—but its function outside the brain was unknown.
Morrell et al. now find that glutamate increases platelet activation and 
clumping. Glutamate treatment increased the expression of clot-inducing 
adhesion molecules on platelets that were activated with thrombin—a blood 
enzyme that becomes activated during infection or injury. The platelets carried 
glutamate receptors, which flood the cell with sodium ions when stimulated. 
Sodium triggers a structural change in thrombin receptors, which might 
enhance their affinity for thrombin. Mice lacking glutamate receptors and those 
treated with drugs that block them were slow to form clots.
The authors speculate that, like neurons, activated platelets form 
synapses with neighboring platelets into which they spew glutamate. 
The high glutamate concentration within these spaces might keep the 
cells stuck together and further enlarge the clot by snaring more platelets, 
which then add to the 
glutamate pool. Drugs 
that block glutamate 
receptors might be 
potentially useful in 
preventing stroke, heart 
attacks, and other 
diseases that can be 
triggered by clots. 
Regulatory T cell brakes 
On  page  565, Haxhinasto et al. pinpoint the signaling roadblock 
that stops CD4+ T cells from turning into regulatory T (T reg) cells. 
Some T reg cells develop directly from thymic progenitor cells, but 
others seem to be converts that were once CD4+ T cells. These poten-
tially inflammatory CD4+ T cells turn into immune-suppressing T reg 
cells when they simultaneously bind antigen and the cytokine TGF-β. 
The mechanism that flips this switch was unknown. 
T reg cells have less PI3K/Akt signaling, which promotes T cell 
proliferation and survival. The authors now find that the suppression of 
Akt allows CD4+ T cells to convert. Activated CD4+ T cells that were 
forced to express Akt were unable to turn on T reg cell–specific genes, 
including the transcription factor Foxp3. The expression of Akt did not, 
however, prevent the development of T reg cells from immature thymic 
T cells that had already turned on Foxp3. Foxp3 levels in these T reg 
cells were stable, perhaps because the gene becomes fixed in an active 
state by chromatin modifications.
The perpetual activation of Akt leads to overactive T cells that can 
trigger autoimmunity and the rejection of transplanted organs. Blockade 
of Akt signaling using the drug rapamycin can prevent organ rejection. 
The group found that activated, rapamycin-treated CD4+ T cells expressed 
Foxp3 and other T reg cell–specific genes, suggesting that the drug helps 
replace offensive T cells with defensive T reg cells. 
Granules live and let die
Healthy eating and sleeping habits prolong 
human life, but neutrophils leave their lon-
gevity in the hands of granules, say Conus et al. 
(page 685).
Neutrophils that ingest bacteria die after 
killing their prey, thereby reining in their in-
flammatory effects. The authors wondered 
whether neutrophil granules, which are loaded 
with enzymes and chemicals that kill the 
bacteria, also kill the neutrophils.
Conus et al. now find that granules release 
cathepsin D, a protease known to cause non-
apoptotic death in other cell types. In neu-
trophils, however, cathepsin D activated an 
apoptotic cascade by cleaving caspase-8. Because 
cathepsin D is only active in acidic environments, 
how it snips caspase-8 in the neutral cytosolic 
pH is unclear. Perhaps the spilling of the acidic 
contents of the granules lowers the pH nearby.
The granules released cathepsin D when 
their membranes were punctured by reactive 
oxygen species (ROS)—inflammatory byprod-
ucts that gradually build up in cells. Neutrophils 
from humans who lack an ROS-generating 
enzyme therefore lived longer.
Neutrophils from patients suffering from 
sepsis—a prolonged system-wide inflamma-
tion—also lived longer than normal neutro-
phils. Their granules were kept intact by 
neutrophil survival cytokines, which are 
produced during inflammation, until ROS 
levels rose high enough to supersede the cyto-
kine effects. What skews the balance between 
these cytokines and ROS in septic patients is 
not known, but the development of therapies 
that artificially rupture the granules might 
help speed their recovery. 
Cathepsin D leaks out of the punctured membranes 
(arrows) of a granule and triggers neutrophil 
apoptosis.
Mice injected with glutamate receptor–blocking 
drugs (left) form fewer clots (spots).